Pulmonary Hypertension Screening in Scleroderma
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: PHTN in Scleroderma Patients. Базовые параметры: 18 лет — 80 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Список центров уточняется — проверьте первичный протокол.
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
Screening for pulmonary hypertension in scleroderma patients
Подробное описание
Scleroderma is a heterogenous connective tissue disorder characterized by fibrosis of the skin, with or without internal organ involvement. The aetiology of scleroderma may involve both environmental and genetic factors. Abnormalities involving the immune system, vascular tissue and extracellular matrix have been demonstrated.
One of the major cause of mortality in patients with scleroderma is pulmonary arterial hypertension (PAH). International recommendations advise annual screening for the early detection of PAH in asymptomatic patients with scleroderma.
scleroderma is group 1 in clinical classification of pulmonary hypertension Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of mean pulmonary arterial pressure (mPAP) \>20 mmHg, assessed by right heart catheterisation. Pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) distinguish pre-capillary PH (PAWP ≤15 mmHg, PVR \>2 Wood Units (WU)), isolated post-capillary PH (PAWP \>15 mmHg, PVR ≤2 WU) and combined post- and pre-capillary PH (PAWP \>15 mmHg, PVR \>2 WU) Scleroderma has an annual prevalence of one to five cases for every 1000 individuals and nearly 15 percent of all cases develop PAH. A diagnosis of PAH in Scleroderma is virtually a death sentence, with studies reporting a mortality rate of 50 per cent in the 3 years of diagnosis. Therefore, developing and implementing screening and diagnosis protocol is important in the fight against this disease. echocardiography as the leading screening tool for scleroderma -PAH. In particular, systolic pulmonary arterial pressure (sPAP) and tricuspid regurgitation velocity (TRV). Echocardiography is non invasive tool for eary screening in pulmonary hypertension according ESC-ERS guideline If the peak tricuspid regurgitation velocity (TRV) is ≤ 2.8 m/s or not measurable, and there are no other echocardiographic signs of pulmonary hypertension, the probability is low.
If the TRV is ≤ 2.8 m/s or not measurable, but other echocardiographic signs of pulmonary hypertension are present, the probability is intermediate low
If the TRV is between 2.9 and 3.4 m/s and no other signs are present, the probability is intermediate high
If the TRV is between 2.9 and 3.4 m/s and other signs are present, the probability is high.
PH probability LOW → other causes . PH probability ntermediate low → follow up Echocardiography PH probability INTERMEDIATE high or HIGH → right heart catheterization Additional echocardiographic signs suggestive of pulmonary hypertension
A: The ventricles
RV/LV basal diameter area ratio ≥1.0
Flattening of the interventricular septum (LVEI \>1.1 in systole and/or diastole)
TAPSE / sPAP ratio \<0.55 mm/mmHg
B: Pulmonary artery
RVOT AT \<105 ms and/or mid-systolic notching
Early diastolic pulmonary regurgitation velocity \>2.2 m/s
PA diameter \>25 mm
RPA diameter \>25 mm
C: Inferior vena cava and RA
IVC diameter \>21 mm with decreased inspiratory collapse (\<50% with a sniff or \<20% with quiet inspiration)
RA area (end-systole) \>18 cm²
Первичные конечные точки
- Screening for pulmonary hypertension in scleroderma patients [Срок оценки: baseline]
Критерии участия
Критерии включения
- . Inclusion criteria: aga ≥18 years confirmed diagnosis of scleroderma
Критерии исключения
- aga <18 years
- patients refused to participate
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
Список центров уточняется — проверьте первичный протокол.
Публикации
- Chennakesavulu PV, Uppaluri S, Koyi J, Jhaveri S, Avanthika C, Sakhamuri LT, Ashokbhai PK, Singh P. Pulmonary Hypertension in Scleroderma- Evaluation and Management. Dis Mon. 2023 Jul;69(7):101468. doi: 10.1016/j.disamonth.2022.101468. Epub 2022 Sep 24. PMID 36163292
- Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, Badesch D, Montani D. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024 Oct 31;64(4):2401324. doi: 10.1183/13993003.01324-2024. Print 2024 Oct. PMID 39209475
- Brown Z, Proudman S, Morrisroe K, Stevens W, Hansen D, Nikpour M. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. Semin Arthritis Rheum. 2021 Jun;51(3):495-512. doi: 10.1016/j.semarthrit.2021.03.011. Epub 2021 Apr 4. PMID 33857705
- Chen K, See A, Shumack S. Epidemiology and pathogenesis of scleroderma. Australas J Dermatol. 2003 Feb;44(1):1-7; quiz 8-9. doi: 10.1046/j.1440-0960.2003.06301.x. PMID 12581091
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ER PMID 36017548
Идентификаторы
NCT: NCT07186439 · PHTN in scleroderma